Androgen deprivation in prostate cancer: first do no harm

Fred Saad¹

Affiliations

Comment

Fred Saad. Lancet Oncol. 2017 Sep.

. 2017 Sep;18(9):1142-1144.

doi: 10.1016/S1470-2045(17)30573-9. Epub 2017 Jul 28.

Fred Saad¹

¹ University of Montreal Hospital Center, Montreal, QC H2X 0A9, Canada. Electronic address: fred.saad@umontreal.ca.

No abstract available

Comment on

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, D'Este C, Frydenberg M, Loblaw A, Malone S, Millar J, Tai KH, Turner S. Duchesne GM, et al. Lancet Oncol. 2017 Sep;18(9):1192-1201. doi: 10.1016/S1470-2045(17)30426-6. Epub 2017 Jul 28. Lancet Oncol. 2017. PMID: 28760403 Clinical Trial.